公开(公告)号：CY1120480T1

公开(公告)日：2019-07-10

申请号：CY181100786

申请日：2018-07-30

Applicant: UNIV HEALTH NETWORK

Inventor： LAUFER RADOSLAW ,  NG GRACE ,  LI SZE-WAN ,  PAULS HEINZ W ,  LIU YONG ,  PATEL NARENDRA KUMAR B

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

Abstract: Ηπαρούσαδιδασκαλίαπαρέχειμίαένωσηη οποίαπαριστάνεταιμετονακόλουθοδομικότύπο: (Τύπος (I)), ήέναφαρμακευτικάαποδεκτόάλαςαυτής. Επίσηςπεριγράφονταιφαρμακευτικέςσυνθέσειςκαιμέθοδοιχρήσηςαυτών.

公开(公告)号：ME03093B

公开(公告)日：2019-01-20

申请号：MEP2018171

申请日：2014-11-14

Applicant: UNIV HEALTH NETWORK

Inventor： LAUFER RADOSLAW ,  NG GRACE ,  LI SZE-WAN ,  PAULS HEINZ W ,  LIU YONG ,  PATEL NARENDRA KUMAR B

IPC: A61K31/519 ,  A61P35/00 ,  C07D487/04

公开(公告)号：HUE039351T2

公开(公告)日：2018-12-28

申请号：HUE14861448

申请日：2014-11-14

Applicant: UNIV HEALTH NETWORK

Inventor： LAUFER RADOSLAW ,  NG GRACE ,  LI SZE-WAN ,  PAULS HEINZ W ,  LIU YONG ,  PATEL NARENDRA KUMAR B

IPC: A61P35/00

公开(公告)号：CA2989684A1

公开(公告)日：2016-12-29

申请号：CA2989684

申请日：2016-06-23

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  PATEL NARENDRA KUMAR B ,  PAULS HEINZ W ,  LI SZE-WAN ,  NG GRACE ,  LAUFER RADOSLAW ,  LIU YONG ,  LANG YUNHUI

IPC: C07D495/04 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/551 ,  A61K39/395 ,  A61P35/00

Abstract: Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).

公开(公告)号：PL3322711T3

公开(公告)日：2021-10-25

申请号：PL16813437

申请日：2016-06-23

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  PATEL NARENDRA KUMAR B ,  PAULS HEINZ W ,  LI SZE-WAN ,  NG GRACE ,  LAUFER RADOSLAW ,  LIU YONG ,  LANG YUNHUI

IPC: C07D495/04 ,  A61K31/4355 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/551 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

公开(公告)号：SI3322711T1

公开(公告)日：2021-08-31

申请号：SI201631189

申请日：2016-06-23

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  PATEL NARENDRA KUMAR B ,  PAULS HEINZ W ,  LI SZE-WAN ,  NG GRACE ,  LAUFER RADOSLAW ,  LIU YONG ,  LANG YUNHUI

IPC: C07D495/00 ,  A61K31/00 ,  A61K39/00 ,  A61K45/00 ,  A61P35/00 ,  C07K16/00

公开(公告)号：HRP20210895T1

公开(公告)日：2021-08-20

申请号：HRP20210895

申请日：2021-06-07

Applicant: UNIV HEALTH NETWORK

Inventor： SAMPSON PETER BRENT ,  PATEL NARENDRA KUMAR B ,  PAULS HEINZ W ,  LI SZE-WAN ,  NG GRACE ,  LAUFER RADOSLAW ,  LIU YONG ,  LANG YUNHUI

IPC: C07D495/04 ,  A61K31/4355 ,  A61K31/4436 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/551 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

公开(公告)号：CA2889919C

公开(公告)日：2021-08-17

申请号：CA2889919

申请日：2013-11-15

Applicant: UNIV HEALTH NETWORK

Inventor： LIU YONG ,  PAULS HEINZ W ,  LAUFER RADOSLAW ,  LI SZE-WAN ,  SAMPSON PETER BRENT ,  FEHER MIKLOS ,  NG GRACE ,  PATEL NARENDRA KUMAR B ,  LANG YUNHUI

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

Abstract: The present teachings provide a compound represented by structural formula (1-0), or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

公开(公告)号：NZ707432A

公开(公告)日：2020-01-31

申请号：NZ70743213

申请日：2013-11-15

Applicant: UNIV HEALTH NETWORK

Inventor： LIU YONG ,  PAULS HEINZ W ,  LAUFER RADOSLAW ,  LI SZE-WAN ,  SAMPSON PETER BRENT ,  FEHER MIKLOS ,  NG GRACE ,  PATEL NARENDRA KUMAR B ,  LANG YUNHUI

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00

Abstract: The present teachings provide a compound represented by structural formula (II-A0), or a pharmaceutically acceptable salt thereof. R1 is –NHRb1, where Rb1 is alkyl which may be optionally substituted with one or more groups as defined herein. R2 is optionally substituted heterocycloalkyl, heteroaryl, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted heterocyclyloxy or substituted amino (and wherein the substituents are as defined herein). R4 is chloro or methyl. Rd is cyclopropyl. Specific compounds include N-cyclopropyl-4-(7-(((trans-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(pyridin-3-yloxy)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide (CFI-402257) and N-cyclopropyl-4-(7-((cyclopropylmethyl)amino)-5-(((1S,2R)-2-hydroxycyclohexyl)amino)pyrazolo[1,5-a]pyrimidin-3-yl)-2-methylbenzamide. Also described are pharmaceutical compositions and uses thereof, such as for the inhibitors of tyrosine threonine kinase (TTK) and for the treatment of cancers such as pancreatic cancer, prostate cancer, lung cancer, melanoma, breast cancer, colon cancer, or ovarian cancer.

公开(公告)号：HRP20181041T1

公开(公告)日：2018-09-21

申请号：HRP20181041

申请日：2018-07-05

Applicant: UNIV HEALTH NETWORK

Inventor： LAUFER RADOSLAW ,  NG GRACE ,  LI SZE-WAN ,  PAULS HEINZ W ,  LIU YONG ,  PATEL NARENDRA KUMAR B

IPC: C07D487/04 ,  A61K31/519 ,  A61P35/00